Access TOC
Download Data
October 2024
The global microbial fermentation technology market size was estimated at US$ 34.11 billion in 2023 and is projected to grow US$ 60.17 billion by 2033, rising at a compound annual growth rate (CAGR) of 5.84% from 2024 to 2033. The market is growing due to increasing demand for biologics.
Unlock Infinite Advantages: Subscribe to Annual Membership
Microorganisms and enzymes are used in the microbial fermentation technology market to create molecules that are used in the food, chemical, pharmaceutical, energy, and material sectors. With thousands of years of usage under its belt, fermentation is a very old method. This was its initial application in the brewing of beer. In order to produce value-added products like hormones, enzymes, antibiotics, and other metabolites, fermentation technology and biotechnology have combined today. Numerous industrial items make extensive use of fermentation technology. Fermentation technology is widely used in the manufacturing of fermented drinks (wine, beer, whiskey), organic solvents (acetone, alcohols), enzymes, amino acids, vitamins, medicines, and other items.
The microbial fermentation technology market is a bright, innovative, and quickly expanding area that uses microbes to produce compounds that are extremely useful for the food, pharmaceutical, biofuel, and environmentally friendly material industries, as well as for energy and fine chemicals production. Although this technology has been employed for many years to produce highly valuable goods, in order to facilitate the shift to a bio-based society, it is imperative that the development of microbial fermentation technology be further accelerated.
| Company Name | DMC Biotechnologies |
| Headquarters | Colorado, U.S. |
| Pipeline | In June 2024, Danone, Michelin, DMC Biotechnologies, a start-up, and Crédit Agricole Centre France together established the Biotech Open Platform to advance precision fermentation technology. The Parc Cataroux Sustainable Materials Center, an innovation hub in Clermont-Ferrand, France, financed by Michelin, is home to the platform. The platform will boost the production of bio-based materials and ingredients with an initial investment of more than 16 million euros, with support from many public and private entities. The platform seeks to fast-track the advancement of precision fermentation by expanding new, laboratory-tested products and techniques. A second line will be built in the upcoming years, and by 2025, a production line demonstration complete with a purification unit and fermenter will be put in place. |
| Company Name | Bored Cow |
| Headquarters | New York, U.S. |
| Pipeline | In May 2024, the pioneer of dairy without animal testing, Bored Cow, is announcing its entry into 2,000 Albertsons shops throughout the country. A major turning point for food and climate technology has been reached when a dairy product produced using precision fermentation is now sold in retail establishments across all 50 states for the first time. |
Recently, complete biomass products like mycoprotein have been produced from microorganisms via fermentation. This novel protein may be able to satisfy the increased demand for high-protein meals in the future, providing a sustainable substitute and, consequently, food security for a population that is always expanding, all while minimizing environmental harm. Furthermore, genetically engineered microbes with the capacity to release a wide variety of enzymes are produced in part through fermentation. They may, therefore, be grown on a variety of substrates, including garbage, and new products can be made. Therefore, fermentation plays a role in the production of sustainable food items.
For instance,
During the projection period, the microbial fermentation technology market is expected to encounter significant growth constraints due to the high cost of equipment and raw materials, as well as ongoing price fluctuations driven by various political, economic, and social variables. The trade relations that are now affecting the price of gasoline, as it is represented in the transportation sector, have a significant influence on the price of raw materials in the global market. Because maintaining product consistency is essential to sustaining a high brand value over time, the lack of resources may restrict the commercialization of the worldwide microbial fermentation technology market. Furthermore, as demand is growing at an exponential pace and market participants have a limited amount of time to supply the finished items, the microbial fermentation technology business may encounter difficulties scaling up the production process on schedule.
It has only recently come to light that precision fermentation technology has the ability to manufacture food and food components in an environmentally friendly manner. The latest development in the history of animal-free food production is precision fermentation. Precision fermentation involves the use of bioengineering techniques to genetically program bacteria to generate a desired molecule when fermented under certain circumstances. The creation of vast quantities of certain chemicals is made possible by this kind of precision fermentation.
For instance,
The antibiotics segment captured the largest microbial fermentation technology market share in 2023. Medicinal proteins, insulin, enzymes, and antibiotics are among the microorganisms that are grown by fermentation in the pharmaceutical sector. One important area of applied microbiology is the microbial synthesis of antibiotics through secondary metabolism. Of the bioactive molecules that can be fermented to extract them from microbes, antibiotics are the most significant class. Utilizing cell immobilization to separate the development of the cells and the generation of metabolites is a useful way to enhance the process, as the production of antibiotics is linked to non-growth.
The CMOs and CDMOs segment held the largest microbial fermentation technology market share by 44% in 2023. Throughout the whole product life cycle—from preclinical to clinical trial to commercial phases, from process development to the full manufacturing process for the finished medicinal product—CMOs offer comprehensive assistance and pilot-to-commercial microbial fermentation capabilities. The manufacture of fermentation products in cGMP compliance may be achieved through the use of various microbial expression methods for fed-batch and perfusion, as well as cell banking services ranging from cell line generation to cryogenic preservation. Pharmaceutical production businesses may be confident they will receive fermentation products of the highest caliber that have been produced in compliance with set criteria and guidelines by outsourcing to cGMP-compliant microbial manufacturing.
Asia Pacific dominated the microbial fermentation technology market by 47% in 2023. Growth in the regional market may be aided by reasons such as increased disposable income, an increase in players, and rising demand in the food and beverage industry due to population growth. Given the tremendous promise that fermentation technology provides in the food and beverage industry, the technology is seeing an increase in investments in the region. Moreover, encouraging government policies that promote the expansion of the food and feed industries in China, India, Japan, and other nations may also serve as regional industry boosters. The Middle East is predicted to have a strong CAGR due to increased attention being paid to food safety. There is a huge market in these nations for high-quality, nutritious food items and pharmaceuticals.
For instance,
North America is expected to grow at the fastest rate of 25% during the forecast period. The microbial fermentation technology market is expanding due to the growing number of contract development organizations and the increasing involvement of enterprises in research and development. In addition, the U.S. FDA maintains a robust regulatory framework and continuously works to improve the criteria pertaining to the development, promotion, approval, legal procedures, and acceptance of biopharmaceutical goods. Because it has very advanced manufacturing methods for GMP, the U.S. is the major contributor in North America.
The USDA guaranteed a $25 million loan to Liberation Labs, a precision fermentation company in the U.S., to expedite the building of a plant in Indiana. According to GFI, the Defense Advanced Research Projects Agency (DARPA) will finance fermentation with a total of about $40 million over the course of four years; this amount almost matches the whole amount of money the U.S. has ever invested in alternative proteins before 2023. In 2023, seven new fermentation facilities made their debut, and many others were either shown or started to be built. In the United States, two notable instances are the 100,000-square-foot commercial plant of Meati Foods located in Thornton, Colorado and the 600,000-liter facility of Liberation Labs that was built in Indiana.
By Application
By End-user
By Region
October 2024
October 2024
October 2024
September 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts